Valeant Pharmaceuticals International, Inc. (VRX) PT Lowered to $18.00 at Royal Bank Of Canada

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its price target reduced by equities research analysts at Royal Bank Of Canada from $21.00 to $18.00 in a report released on Friday. The firm currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 44.23% from the stock’s previous close.

A number of other equities analysts have also recently commented on VRX. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research report on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday, August 10th. Wells Fargo & Co reiterated an “underperform” rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a research report on Saturday, September 30th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Five research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and a consensus target price of $17.56.

Valeant Pharmaceuticals International (VRX) traded down 1.562% during mid-day trading on Friday, reaching $12.285. The company had a trading volume of 6,961,752 shares. The firm has a 50-day moving average price of $13.85 and a 200 day moving average price of $13.58. The firm’s market capitalization is $4.28 billion. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS. Analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) PT Lowered to $18.00 at Royal Bank Of Canada” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/20/valeant-pharmaceuticals-international-inc-vrx-given-new-18-00-price-target-at-royal-bank-of-canada.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.87% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Armstrong Henry H Associates Inc. boosted its stake in Valeant Pharmaceuticals International by 0.3% during the second quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock worth $1,622,000 after acquiring an additional 295 shares in the last quarter. Eaton Vance Management boosted its stake in Valeant Pharmaceuticals International by 1.2% during the second quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 500 shares in the last quarter. IFP Advisors Inc boosted its stake in Valeant Pharmaceuticals International by 0.4% during the second quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after acquiring an additional 509 shares in the last quarter. NEXT Financial Group Inc boosted its stake in Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after acquiring an additio

A number of other equities analysts have also recently commented on VRX. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research report on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday, August 10th. Wells Fargo & Co reiterated an “underperform” rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a research report on Saturday, September 30th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Five research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and a consensus target price of $17.56.

Valeant Pharmaceuticals International (VRX) traded down 1.562% during mid-day trading on Friday, reaching $12.285. The company had a trading volume of 6,961,752 shares. The firm has a 50-day moving average price of $13.85 and a 200 day moving average price of $13.58. The firm’s market capitalization is $4.28 billion. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS. Analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) PT Lowered to $18.00 at Royal Bank Of Canada” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/20/valeant-pharmaceuticals-international-inc-vrx-given-new-18-00-price-target-at-royal-bank-of-canada.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.87% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Armstrong Henry H Associates Inc. boosted its stake in Valeant Pharmaceuticals International by 0.3% during the second quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock worth $1,622,000 after acquiring an additional 295 shares in the last quarter. Eaton Vance Management boosted its stake in Valeant Pharmaceuticals International by 1.2% during the second quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 500 shares in the last quarter. IFP Advisors Inc boosted its stake in Valeant Pharmaceuticals International by 0.4% during the second quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after acquiring an additional 509 shares in the last quarter. NEXT Financial Group Inc boosted its stake in Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after acquiring an additional 600 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its stake in Valeant Pharmaceuticals International by 3.8% during the second quarter. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company’s stock worth $379,000 after acquiring an additional 800 shares in the last quarter. 50.44% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply